Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Point of Care Detection of Prostate Specific Antigen

Principal Investigator
Name
Takako Takeda
Degrees
Ph.D.
Institution
Triton Systems, Inc.
Position Title
Sr. Data Scientist
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-1685
Initial CDAS Request Approval
Sep 30, 2024
Title
Point of Care Detection of Prostate Specific Antigen
Summary
Triton will develop a low-cost, at-home, paper-based vertical flow assay PSA detection test kit with prostate
cancer biopsy risk calculation algorithm based on our previously developed technologies with a classifier for
prostate cancer risk integrating the personal risk factors using a finger stick to obtain a blood sample at the
price less than $20.00. Successful development of a low cost, simple-to-use, home-based test kit for PSA
screening for prostate cancer with a classification algorithm will enable patients to decide whether to seek
medical help or keep monitoring, will be reducing cancer mortality especially for high risked population.
Aims

Our Aim 1 is to develop a rapid, ease of use, paper-based vertical flow assay prototype that patients can
administer to detect PSA based on triton’s previously developed technology. Aim 2 is to develop a classifier
model for PSA screening with the readout from the proposed device and patient’s personalized risk factors
including race, age, geography, and family history with machine learning technique. Anticipated end results
of the proposed Phase I efforts include a functional prototype for a point-of-care PSA screening blood test
with optimized reagent formulation with a classification model.

Collaborators

Dr. Jonathan Shoag – University Hospitals Cleveland & Case Western Reserve University

Dr. Alex Bryant – the University of Michigan